Generic hepatitis C drugs continue to produce high cure rates

Treatment with generic versions of direct-acting antiviral drugs continues to produce similar cure rates to those reported in clinical trials, Dr James Freeman reported last week at the International Liver Congress in Amsterdam. Dr James Freeman, an Australian general practitioner based in Hobart, Tasmania, was reporting on the outcomes of people with hepatitis C who imported generic versions of direct-acting antivirals manufactured in India and elsewhere

AbbVie takes aim at Gilead and BMS with 8-week hep C treatment

AbbVie is aiming to steal sales from hep C drugs from Gilead and BMS with a new combination offering a shorter, eight-week treatment for the most difficult-to-treat form of the disease. Results presented at the International Liver Congress (ILC) in Amsterdam showed 95% of genotype 3 patients on its pan-genotypic regimen of glecaprevir+pibrentasvir were free of disease, 12 weeks after completing an eight-week treatment course. The results were based on

MicroRNA-34a as a Therapeutic Target in HCC

MicroRNA-34a, one of the most documented tumor suppressor microRNAs, is being evaluated as a potential therapeutic target in hepatocellular carcinoma (HCC) in a study being presented at the 2017 International Liver Congress. Results from a study of microRNA-34a and natural killer (NK) cells suggest that microRNA-34a could have a role in regulating cytotoxicity and development of the effector NK cells and their target cells. Lead author Amira Abdelhamid

Independent Prognostic Markers of HCC Recurrence Identified

Higher levels of hepatocytes positive for pERK immunostaining and greater microvascular invasion have emerged as independent prognostic factors of recurrence in patients following sorafenib (Nexavar) treatment for hepatocellular carcinoma (HCC), researchers reported at the 2017 International Liver Congress in Amsterdam. “The is an unmet need for adjuvant treatment for HCC since HCC recurrence after resection or ablation occurs in 70% of patients within 5 y

Higher Risk of HCC Recurrence Observed Following DAA Therapy for Hepatitis C

In updated results presented at the 2017 International Liver Congress, Spanish researchers raised a red flag regarding observations of unexpected higher rates of hepatocellular carcinoma (HCC) recurrence following treatment with direct-acting antivirals (DAAs) for hepatitis C virus (HCV) infection. Maria Reig MD, PhD, presented data updating results published last year evaluating increased rates of tumor recurrence in patients following successful treatme

ILC 2017: Investigational dose of oral interferon-free treatment can cure hepatitis C in children

The study evaluated the use of a direct-acting antiviral treatment in children aged 6 to 11, for whom the standard of care has been pegylated interferon plus ribavirin April 21, 2017, Amsterdam, The Netherlands: A study presented today that evaluated an investigational dosage of once-daily ledipasvir 45 mg/sofosbuvir 200 mg (LDV/SOF) in children aged six to 11 years infected with the Hepatitis C virus (HCV), found that 99% of children (n=89/90) had undete

The Week in Review: April 14, 2017 – April 21, 2017

Friday, April 21, 2017 News Recap Canada Well the last report from the final leg of HepCBC’s Road Trip to BC’s Interior 2017 is in. What a journey!! – and so much work!! This report focusses on events in the Kootenay region of BC, and I’m really impressed at how much Rosemary and Cheryl were able to accomplish!  Amazing. Awareness of hepatitis C in BC’s more remote and small communities is growing and this is due to the hard work of the many advocat...

ILC 2017: Curing hepatitis C reduces cardiovascular risk

Curing hepatitis C reduces the risk of cardiovascular events in people with compensated cirrhosis, a large French study presented this week at the International Liver Congress in Amsterdam shows. Presenting the findings, Patrice Cacoub of Hôpital Pitié-Salpêtrière, Paris, stressed the importance of thinking of hepatitis C as a systemic disease that affects the heart, the kidneys, blood vessels, the brain and glucose metabolism through mechanisms that are

ILC 2017: European countries restrict access to life-saving treatment for hepatitis C

A review of recent reimbursement data showed considerable variability in access to direct-acting antiviral therapy based on amount of liver scarring and substance use — European Association for the Study of the Liver April 20, 2017, Amsterdam, The Netherlands: Data presented today demonstrate that there are considerable restrictions in the reimbursement of direct-acting antiviral (DAA) therapy across European countries, particularly with respect to th

Hepatitis C Patients at No Elevated Risk of Developing HCC Following DAA Compared to Interferon

Patients were at no elevated risk of developing hepatocellular carcinoma (HCC) after achieving sustained virologic response (SVR) following treatment with direct-acting antiviral therapy (DAA) for hepatitis C compared to interferon therapy, according to results of a meta-analysis reported at the 2017 International Liver Congress (ILC). The data reflected that there was no difference in liver cancer risk following cure with either therapy. However, achievi